IP Verse

Subcutaneous Formulations Of Anti-Cd38 Antibodies And Their Uses

Patent No. EP3827845 (titled "Subcutaneous Formulations Of Anti-Cd38 Antibodies And Their Uses") was filed by Janssen Biotech on Nov 1, 2016. The application was issued on Mar 30, 2022.

Patent Summary

Patent Family

Patent Family

Patent Oppositions (6)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
STORZDec 29, 2022MICHALSKI HUTTERMANN & PARTNER PATENTANWALTE MBB
PATENT BOUTIQUEDec 29, 2022PATENT BOUTIQUE
KONIG SZYNKA TILMANN VON RENESSEDec 27, 2022KONIG SZYNKA TILMANN VON RENESSE PATENTANWALTE PARTNERSCHAFT MBB DUSSELDORF
DR H ULRICH DORRIESDec 22, 2022DORRIES
DR H ULRICH DORRIESDec 22, 2022DORRIES, HANS ULRICH , DF-MP DORRIES FRANK-MOLNIA & POHLMAN
XBRANE BIOPHARMADec 21, 2022YILDIRIM

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP3827845

JANSSEN BIOTECH
Application Number
EP20215879A
Filing Date
Nov 1, 2016
Status
Granted And Under Opposition
Feb 25, 2022
Publication Date
Mar 30, 2022
External Links
Slate, Register , Google Patents